Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has received written notification from the NASDAQ Stock Market (“NASDAQ”) that it has determined to delist the Company’s shares from the NASDAQ Capital Market (“Capital Market”), and will suspend trading in the Company’s shares at the open of business on Friday, May 5, 2017, since the Company no longer satisfies the Capital Market’s listing requirements, specifically the requirement to maintain a minimum of $2.5 million in stockholders’ equity. The letter also stated that NASDAQ will complete the delisting by filing a Form 25 Notification of Delisting with the Securities and Exchange Commission (SEC). The Company has filed an application to have its shares quoted on the OTCQB® Market (“OTCQB”), which is operated by OTC Market Groups Inc., under the symbol “WINT” and anticipates that its shares will begin to trade on the OTCQB effective Friday, May 5, 2017.
The company’s Return on Assets were -184.00%%. At the close of the day, the stock reported a Market Cap of $7.95M in the Biotechnology Industry.
The company traded a total volume of 1,243,600, and the stock saw a change of -27.03% in the previous trading session. The company reported a 52-Week High of $-81.67% and a52-Week Low of $-10.99%. The monthly Volatility of Windtree Therapeutics, Inc. stood at 11.41%.
Windtree Therapeutics, Inc. announced EPS of $-4.76. This represents a growth of 40.10%% in EPS this year compared to what was reported last financial year and represents an overall growth of 18.20%% over the past five year.
Windtree Therapeutics, Inc.’s ownership was spread out with Insider Ownership amounting to 0.10% while Institutional Ownership amounted to 27.20%.
Return on Assets reported was -184.00%%. Return on Equity for the financial year was 219.80%% while Return on Investments was 1000.90%%. Current and quick ratio amounted to 0.50 and 0.50 respectively.
The company has 9.82M shares outstanding at a price of $0.81 per share.
EPS growth reported for this year was 40.10%%. For the past five years, the company has reported EPS growth of 18.20%% with EPS growth for the next year projected to be -37.30%.